MEX-NM-301<\/a> <\/p><\/blockquote>\n\n\n\n<\/p>\n","protected":false},"excerpt":{"rendered":"
L’essai clinique de phase III, MEX-NM-301, d\u00e9marre \u00e0 I-Motion. Cette \u00e9tude ouverte non comparative vise \u00e0 \u00e9valuer la pharmacocin\u00e9tique, l\u2019innocuit\u00e9 et l\u2019efficacit\u00e9 de la mexil\u00e9tine \u00e0 l\u2019\u00e9tat d\u2019\u00e9quilibre chez l\u2019adolescent et l\u2019enfant pr\u00e9sentant des troubles myotoniques. La mexil\u00e9tine est un agent bloquant du canal sodique indiqu\u00e9, chez l’adulte; en France, dans le traitement symptomatique des … Continued<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2400","post","type-post","status-publish","format-standard","hentry","category-non-classifiee"],"acf":[],"yoast_head":"\nOuverture de l'\u00e9tude de phase III \u00e9valuant la mexil\u00e9tine chez l'enfant et l'adolescent pr\u00e9sentant des troubles myotoniques - I-Motion<\/title>\n<meta name=\"description\" content=\"L'essai clinique de phase III, MEX-NM-301, d\u00e9marre \u00e0 I-Motion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ouverture de l'\u00e9tude de phase III \u00e9valuant la mexil\u00e9tine chez l'enfant et l'adolescent pr\u00e9sentant des troubles myotoniques - I-Motion\" \/>\n<meta property=\"og:description\" content=\"L'essai clinique de phase III, MEX-NM-301, d\u00e9marre \u00e0 I-Motion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/\" \/>\n<meta property=\"og:site_name\" content=\"I-Motion\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-23T12:34:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-08-23T12:34:49+00:00\" \/>\n<meta name=\"author\" content=\"Anne Berthomier\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anne Berthomier\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/\"},\"author\":{\"name\":\"Anne Berthomier\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/ecf0b87715a026a200491fe2d7649def\"},\"headline\":\"Ouverture de l’\u00e9tude de phase III \u00e9valuant la mexil\u00e9tine chez l’enfant et l’adolescent pr\u00e9sentant des troubles myotoniques\",\"datePublished\":\"2021-08-23T12:34:48+00:00\",\"dateModified\":\"2021-08-23T12:34:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/\"},\"wordCount\":102,\"publisher\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#organization\"},\"articleSection\":[\"Non classifi\u00e9(e)\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/\",\"url\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/\",\"name\":\"Ouverture de l'\u00e9tude de phase III \u00e9valuant la mexil\u00e9tine chez l'enfant et l'adolescent pr\u00e9sentant des troubles myotoniques - I-Motion\",\"isPartOf\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#website\"},\"datePublished\":\"2021-08-23T12:34:48+00:00\",\"dateModified\":\"2021-08-23T12:34:49+00:00\",\"description\":\"L'essai clinique de phase III, MEX-NM-301, d\u00e9marre \u00e0 I-Motion.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.institut-myologie.org\/imotion\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ouverture de l’\u00e9tude de phase III \u00e9valuant la mexil\u00e9tine chez l’enfant et l’adolescent pr\u00e9sentant des troubles myotoniques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#website\",\"url\":\"https:\/\/www.institut-myologie.org\/imotion\/\",\"name\":\"I-Motion\",\"description\":\"Plateforme d'essais cliniques p\u00e9diatriques pour les maladies neuromusculaires\",\"publisher\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.institut-myologie.org\/imotion\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#organization\",\"name\":\"Institut I-Motion\",\"url\":\"https:\/\/www.institut-myologie.org\/imotion\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.institut-myologie.org\/imotion\/wp-content\/uploads\/2016\/08\/logoImotion.png\",\"contentUrl\":\"https:\/\/www.institut-myologie.org\/imotion\/wp-content\/uploads\/2016\/08\/logoImotion.png\",\"width\":150,\"height\":51,\"caption\":\"Institut I-Motion\"},\"image\":{\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/ecf0b87715a026a200491fe2d7649def\",\"name\":\"Anne Berthomier\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/86282695a210f7767b59efc8eb542fb81270ad9c1a9d8bb3bccd9ab2f96782e6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/86282695a210f7767b59efc8eb542fb81270ad9c1a9d8bb3bccd9ab2f96782e6?s=96&d=mm&r=g\",\"caption\":\"Anne Berthomier\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ouverture de l'\u00e9tude de phase III \u00e9valuant la mexil\u00e9tine chez l'enfant et l'adolescent pr\u00e9sentant des troubles myotoniques - I-Motion","description":"L'essai clinique de phase III, MEX-NM-301, d\u00e9marre \u00e0 I-Motion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/","og_locale":"fr_FR","og_type":"article","og_title":"Ouverture de l'\u00e9tude de phase III \u00e9valuant la mexil\u00e9tine chez l'enfant et l'adolescent pr\u00e9sentant des troubles myotoniques - I-Motion","og_description":"L'essai clinique de phase III, MEX-NM-301, d\u00e9marre \u00e0 I-Motion.","og_url":"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/","og_site_name":"I-Motion","article_published_time":"2021-08-23T12:34:48+00:00","article_modified_time":"2021-08-23T12:34:49+00:00","author":"Anne Berthomier","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Anne Berthomier","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/#article","isPartOf":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/"},"author":{"name":"Anne Berthomier","@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/ecf0b87715a026a200491fe2d7649def"},"headline":"Ouverture de l’\u00e9tude de phase III \u00e9valuant la mexil\u00e9tine chez l’enfant et l’adolescent pr\u00e9sentant des troubles myotoniques","datePublished":"2021-08-23T12:34:48+00:00","dateModified":"2021-08-23T12:34:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/"},"wordCount":102,"publisher":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/#organization"},"articleSection":["Non classifi\u00e9(e)"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/","url":"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/","name":"Ouverture de l'\u00e9tude de phase III \u00e9valuant la mexil\u00e9tine chez l'enfant et l'adolescent pr\u00e9sentant des troubles myotoniques - I-Motion","isPartOf":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/#website"},"datePublished":"2021-08-23T12:34:48+00:00","dateModified":"2021-08-23T12:34:49+00:00","description":"L'essai clinique de phase III, MEX-NM-301, d\u00e9marre \u00e0 I-Motion.","breadcrumb":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.institut-myologie.org\/imotion\/2021\/08\/23\/ouverture-de-letude-de-phase-iii-evaluant-la-mexiletine-chez-lenfant-et-ladolescent-presentant-des-troubles-myotoniques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.institut-myologie.org\/imotion\/"},{"@type":"ListItem","position":2,"name":"Ouverture de l’\u00e9tude de phase III \u00e9valuant la mexil\u00e9tine chez l’enfant et l’adolescent pr\u00e9sentant des troubles myotoniques"}]},{"@type":"WebSite","@id":"https:\/\/www.institut-myologie.org\/imotion\/#website","url":"https:\/\/www.institut-myologie.org\/imotion\/","name":"I-Motion","description":"Plateforme d'essais cliniques p\u00e9diatriques pour les maladies neuromusculaires","publisher":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.institut-myologie.org\/imotion\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.institut-myologie.org\/imotion\/#organization","name":"Institut I-Motion","url":"https:\/\/www.institut-myologie.org\/imotion\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/logo\/image\/","url":"https:\/\/www.institut-myologie.org\/imotion\/wp-content\/uploads\/2016\/08\/logoImotion.png","contentUrl":"https:\/\/www.institut-myologie.org\/imotion\/wp-content\/uploads\/2016\/08\/logoImotion.png","width":150,"height":51,"caption":"Institut I-Motion"},"image":{"@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/ecf0b87715a026a200491fe2d7649def","name":"Anne Berthomier","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.institut-myologie.org\/imotion\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/86282695a210f7767b59efc8eb542fb81270ad9c1a9d8bb3bccd9ab2f96782e6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/86282695a210f7767b59efc8eb542fb81270ad9c1a9d8bb3bccd9ab2f96782e6?s=96&d=mm&r=g","caption":"Anne Berthomier"}}]}},"_links":{"self":[{"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/posts\/2400","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/comments?post=2400"}],"version-history":[{"count":1,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/posts\/2400\/revisions"}],"predecessor-version":[{"id":2401,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/posts\/2400\/revisions\/2401"}],"wp:attachment":[{"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/media?parent=2400"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/categories?post=2400"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.institut-myologie.org\/imotion\/wp-json\/wp\/v2\/tags?post=2400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}